Have you read about our work yet?

Read the layman explanation of our technologies

Read the technical explanation of our technologies

Why invest?

  • Two development paths: platform technology with the ability to be licensed by others and proprietary therapeutic product development
  • A major step to standardize and simplify a promising approach to cancer therapy that homes in on cancer cells thereby avoiding the nasty side effects of traditional chemotherapeutics
  • Current and future partnerships could lead to early licensing revenue opportunities
  • Potential acquisition target

Contact investor relations

To speak to our investor relations representative, please contact Bill Dickie at Bill.dickie@advancedproteome.com

Officers and Directors:

Bill Dickie
Chief Executive Officer, President, and Director

Dr. Benjamin Krantz

Paul Woodward

Scientific Advisory Board:

Dr. Aditya Bardia
Massachusetts General Hospital Cancer Center

Dr. Greg Thurber
University of Michigan

Prof. Stephen G. Withers
University of British Columbia